A relaxin-based nanotherapy for liver fibrosis
- 25 January 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Nanotechnology
- Vol. 16 (4), 365-366
- https://doi.org/10.1038/s41565-020-00832-w
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosisNature Nanotechnology, 2021
- Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosisThe FASEB Journal, 2019
- Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver diseaseLaboratory Investigation, 2019
- Engineered Relaxin as theranostic nanomedicine to diagnose and ameliorate liver cirrhosisNanomedicine: Nanotechnology, Biology and Medicine, 2019
- Relaxin abrogates renal interstitial fibrosis by regulating macrophage polarization via inhibition of Toll-like receptor 4 signalingOncotarget, 2017
- A single adenovirus-mediated relaxin delivery attenuates established liver fibrosis in ratsThe Journal of Gene Medicine, 2016
- Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertensionin vivoJournal of Hepatology, 2013
- Relaxin decreases the severity of established hepatic fibrosis in miceLiver International, 2013
- Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosisProceedings of the National Academy of Sciences of the United States of America, 2012
- The Relaxin Gene‐Knockout Mouse: A Model of Progressive FibrosisAnnals of the New York Academy of Sciences, 2005